Inhibition of the unfolded protein response reduces arrhythmia risk after myocardial infarction.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
15 09 2021
Historique:
received: 19 01 2021
accepted: 28 07 2021
pubmed: 30 7 2021
medline: 16 11 2021
entrez: 29 7 2021
Statut: ppublish

Résumé

Ischemic cardiomyopathy is associated with an increased risk of sudden death, activation of the unfolded protein response (UPR), and reductions in multiple cardiac ion channels. When activated, the protein kinase-like ER kinase (PERK) branch of the UPR reduces protein translation and abundance. We hypothesized that PERK inhibition could prevent ion channel downregulation and reduce arrhythmia risk after myocardial infarct (MI). MI induced in mice by coronary artery ligation resulted in reduced ion channel levels, ventricular tachycardia (VT), and prolonged corrected intervals between the Q and T waves on the ECGs (QTc). Protein levels of major cardiac ion channels were decreased. MI cardiomyocytes showed significantly prolonged action potential duration and decreased maximum upstroke velocity. Cardiac-specific PERK KO reduced electrical remodeling in response to MI, with shortened QTc intervals, fewer VT episodes, and higher survival rates. Pharmacological PERK inhibition had similar effects. In conclusion, we found that activated PERK during MI contributed to arrhythmia risk by the downregulation of select cardiac ion channels. PERK inhibition prevented these changes and reduced arrhythmia risk. These results suggest that ion channel downregulation during MI is a fundamental arrhythmia mechanism and that maintenance of ion channel levels is antiarrhythmic.

Identifiants

pubmed: 34324437
pii: e147836
doi: 10.1172/JCI147836
pmc: PMC8439592
doi:
pii:

Substances chimiques

7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine 0
Indoles 0
Ion Channels 0
Protein Kinase Inhibitors 0
PERK kinase EC 2.7.11.1
eIF-2 Kinase EC 2.7.11.1
Adenine JAC85A2161

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL104025
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134791
Pays : United States

Références

Nat Rev Cardiol. 2014 Oct;11(10):607-15
pubmed: 24958080
Int J Biochem Cell Biol. 2013 Feb;45(2):438-47
pubmed: 23032698
Heart Rhythm. 2018 Jul;15(7):1072-1080
pubmed: 29454929
Cardiovasc Res. 2007 Jan 1;73(1):48-56
pubmed: 17107669
Int J Mol Sci. 2015 Dec 31;17(1):
pubmed: 26729106
Chem Biol Interact. 2015 Jan 5;225:90-8
pubmed: 25450231
Med Sci Monit. 2016 Dec 30;22:5218-5227
pubmed: 28036323
Endocrinology. 2003 Aug;144(8):3505-13
pubmed: 12865332
PLoS One. 2011;6(11):e27294
pubmed: 22073308
J Mol Cell Cardiol. 2011 Nov;51(5):722-9
pubmed: 21803046
Stem Cells. 2007 Sep;25(9):2350-7
pubmed: 17525236
J Am Heart Assoc. 2018 Apr 20;7(9):
pubmed: 29678826
J Clin Invest. 2008 Jun;118(6):2246-59
pubmed: 18464931
Curr Top Microbiol Immunol. 2018;414:193-213
pubmed: 29026925
J Mol Cell Cardiol. 2005 Mar;38(3):475-83
pubmed: 15733907
Circ Res. 2006 Aug 4;99(3):275-82
pubmed: 16794188
J Mol Cell Cardiol. 2013 Jan;54:25-34
pubmed: 23123323
PLoS One. 2014 Sep 16;9(9):e107635
pubmed: 25226522
J Mol Cell Cardiol. 2018 Apr;117:62-71
pubmed: 29474817
Genes Dev. 1998 Apr 1;12(7):982-95
pubmed: 9531536
IUBMB Life. 2013 Dec;65(12):962-75
pubmed: 24227223
Circ Arrhythm Electrophysiol. 2013 Oct;6(5):1018-24
pubmed: 24036084
Inflammation. 2017 Dec;40(6):1903-1911
pubmed: 28748322
J Mol Cell Cardiol. 2015 Aug;85:168-77
pubmed: 26027784
J Physiol. 2012 Mar 1;590(5):1171-80
pubmed: 22183728
Cardiovasc Res. 2004 Feb 1;61(2):208-17
pubmed: 14736537
J Biol Chem. 2001 Jul 27;276(30):28197-203
pubmed: 11369778
J Mol Cell Cardiol. 2004 Jul;37(1):91-100
pubmed: 15242739
J Mol Cell Cardiol. 2006 Aug;41(2):330-9
pubmed: 16806259
Circulation. 2006 Jan 24;113(3):345-55
pubmed: 16432066
Circ Res. 2017 Mar 3;120(5):862-875
pubmed: 27932512
J Physiol. 2003 Jan 1;546(Pt 1):5-18
pubmed: 12509475
Circulation. 2010 Feb 2;121(4):519-28
pubmed: 20083682
Circulation. 1998 Oct 6;98(14):1383-93
pubmed: 9760292
Circulation. 2010 Jul 27;122(4):361-9
pubmed: 20625112
Am J Pathol. 2004 Sep;165(3):1019-32
pubmed: 15331425
Eur J Pharmacol. 2010 Mar 10;629(1-3):96-103
pubmed: 20006599
Int J Clin Exp Med. 2017;10(1):1051-1058
pubmed: 28794819
Mol Cell Biol. 2002 Jun;22(11):3864-74
pubmed: 11997520
Expert Opin Ther Targets. 2014 Jul;18(7):719-23
pubmed: 24865516
Circ Res. 2009 Oct 9;105(8):737-45
pubmed: 19745168
J Am Coll Cardiol. 2014 Mar 11;63(9):928-34
pubmed: 24361364
Int J Cardiol. 2015 Jul 15;191:36-45
pubmed: 25965594
Am J Physiol. 1999 Jul;277(1):H80-91
pubmed: 10409185
Cell Death Dis. 2013 Apr 04;4:e582
pubmed: 23559016
Cardiovasc Pathol. 2004 May-Jun;13(3):156-64
pubmed: 15081472
Biochem Biophys Res Commun. 2006 Nov 3;349(4):1406-11
pubmed: 16979584
Heart Rhythm. 2017 Mar;14(3):440-447
pubmed: 27989687
Channels (Austin). 2018;12(1):335-345
pubmed: 30165782
Am J Physiol Heart Circ Physiol. 2002 Sep;283(3):H1031-41
pubmed: 12181133
J Biol Chem. 2001 Dec 21;276(51):48309-17
pubmed: 11595740
Chem Biol Interact. 2015 Dec 5;242:99-106
pubmed: 26428355
Circ Res. 1997 Jul;81(1):110-9
pubmed: 9201034
Circ Res. 2004 Apr 16;94(7):874-83
pubmed: 15087427
J Appl Physiol (1985). 2007 Jun;102(6):2104-11
pubmed: 17347379
PLoS One. 2010 Mar 18;5(3):e9746
pubmed: 20305782
J Physiol. 2003 Jan 1;546(Pt 1):119-35
pubmed: 12509483
PLoS One. 2009 Nov 24;4(11):e8008
pubmed: 19956728
Circ Arrhythm Electrophysiol. 2013 Jun;6(3):623-31
pubmed: 23559673
EMBO J. 2005 Mar 23;24(6):1243-55
pubmed: 15775988
PLoS One. 2017 Jun 7;12(6):e0179042
pubmed: 28591178

Auteurs

Man Liu (M)

Division of Cardiology, Department of Medicine, the Lillehei Heart Institute and.

Hong Liu (H)

Division of Cardiology, Department of Medicine, the Lillehei Heart Institute and.

Preethy Parthiban (P)

Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.

Gyeoung-Jin Kang (GJ)

Division of Cardiology, Department of Medicine, the Lillehei Heart Institute and.

Guangbin Shi (G)

Division of Cardiology, Department of Medicine, the Warren Alpert School of Medicine, Brown University and Lifespan Cardiovascular Research Center, Providence, Rhode Island, USA.

Feng Feng (F)

Division of Cardiology, Department of Medicine, the Lillehei Heart Institute and.

Anyu Zhou (A)

Division of Cardiology, Department of Medicine, the Warren Alpert School of Medicine, Brown University and Lifespan Cardiovascular Research Center, Providence, Rhode Island, USA.

Lianzhi Gu (L)

Division of Cardiology, Department of Medicine, the Lillehei Heart Institute and.

Courtney Karnopp (C)

Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.

Elena G Tolkacheva (EG)

Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.

Samuel C Dudley (SC)

Division of Cardiology, Department of Medicine, the Lillehei Heart Institute and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH